Back to Stocks

ALUR

ALLURION TECHNOLOGIES, INC.
1 filings tracked
healthcaremedical devicesMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Allurion Technologies has reached a pivotal inflection point following the February 20, 2026, FDA PMA approval of its Allurion Smart Capsule.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the regulatory milestone, Allurion's financial foundation appears precarious.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ALUR filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The 10-K reveals a company at a crossroads between clinical breakthrough and financial collapse. On one hand, the FDA approval and the clinical synergy with GLP-1s provide a legitimate, high-growth narrative in the obesity sector. On the other, the balance sheet is a distressed landscape of dwindling cash, governance failures, and oppressive debt covenants. The investment thesis now hinges entirely on the speed of the US commercial rollout; the company must generate immediate, massive cash flow to offset its burn rate and satisfy its creditors. Ultimately, Allurion has transitioned from a speculative R&D play to a commercial execution play. While the product's unique value proposition is strong, the margin for error has vanished. Investors are essentially betting that the commercial momentum of the Smart Capsule can outpace the ticking clock of the company's liquidity crisis.

Selected Quarter

Core Takeaway

Allurion has secured the regulatory green light for the US market, but is fighting a battle against time and liquidity to survive long enough to scale.

Investor Lens

The trade-off is between a world-class clinical product and a broken balance sheet.

Watch Next

Quarterly cash burn and the success of the initial US commercial rollout in 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.20Q1 '26 (10-K)

Signal Timeline

Active Filters:Quarter: Q1 '26 (10-K)
bullishMar 30

Obtained FDA PMA approval for the Allurion Smart Capsule in February 2026.

regulatory action
90%
bullishMar 30

Maintained robust gross margins of approximately 63% despite revenue contraction.

margin expansion
70%
bearishMar 30

Frequent use of warrant inducements and private placements to sustain operations.

dilution risk
80%
neutralMar 30

Significant workforce reduction of 65% as part of a strategic restructuring plan.

management change
50%

Filing History

10-KMar 30, 2026
Expand Sequence

The 10-K reveals a company at a crossroads between clinical breakthrough and financial collapse. On one hand, the FDA approval and the clinical synergy with GLP-1s provide a legitimate, high-growth narrative in the obesity sector. On the other, the balance sheet is a distressed landscape of dwindling cash, governance failures, and oppressive debt covenants. The investment thesis now hinges entirely on the speed of the US commercial rollout; the company must generate immediate, massive cash flow to offset its burn rate and satisfy its creditors. Ultimately, Allurion has transitioned from a speculative R&D play to a commercial execution play. While the product's unique value proposition is strong, the margin for error has vanished. Investors are essentially betting that the commercial momentum of the Smart Capsule can outpace the ticking clock of the company's liquidity crisis.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.